Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2005 1
2006 1
2007 2
2008 3
2009 2
2010 2
2011 4
2012 6
2013 10
2014 10
2015 8
2016 4
2017 7
2018 15
2019 17
2020 18
2021 13
2022 9
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Results by year

Filters applied: . Clear all
Page 1
Alemtuzumab-Induced Thyroid Eye Disease: A Comprehensive Case Series and Review of the Literature.
Nirmalan A, Blecher N, Hyder S, Couch SM, Godfrey KJ, Stan MN, Bradley EA, Wagner LH, Tooley AA. Nirmalan A, et al. Ophthalmic Plast Reconstr Surg. 2023 Sep-Oct 01;39(5):470-474. doi: 10.1097/IOP.0000000000002367. Epub 2023 Mar 9. Ophthalmic Plast Reconstr Surg. 2023. PMID: 36893061 Review.
PURPOSE: To present 5 cases of alemtuzumab-induced thyroid eye disease (AI-TED) and review the literature to highlight the natural history, severity, and outcomes as compared with conventional thyroid eye disease (TED). ...
PURPOSE: To present 5 cases of alemtuzumab-induced thyroid eye disease (AI-TED) and review the literature to highlight the nat …
Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis.
Scappaticcio L, Castellana M, Virili C, Bellastella G, Centanni M, Cannavò S, Campennì A, Ruggeri RM, Giovanella L, Trimboli P. Scappaticcio L, et al. J Endocrinol Invest. 2020 Feb;43(2):219-229. doi: 10.1007/s40618-019-01105-7. Epub 2019 Aug 26. J Endocrinol Invest. 2020. PMID: 31452116
PURPOSE: Autoimmune thyroid events (ATEs) are common side effects after alemtuzumab (ALZ) therapy in patients with multiple sclerosis (MS). Our purpose was to reach more robust evidence on prevalence and outcome of the spectrum of alemtuzumab-induced autoimmu …
PURPOSE: Autoimmune thyroid events (ATEs) are common side effects after alemtuzumab (ALZ) therapy in patients with multiple sc …
Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features.
Pariani N, Willis M, Muller I, Healy S, Nasser T, McGowan A, Lyons G, Jones J, Chatterjee K, Dayan C, Robertson N, Coles A, Moran C. Pariani N, et al. J Clin Endocrinol Metab. 2018 Aug 1;103(8):3010-3018. doi: 10.1210/jc.2018-00359. J Clin Endocrinol Metab. 2018. PMID: 29878256 Free PMC article.
CONTEXT: Alemtuzumab, a highly effective treatment for multiple sclerosis (MS), predisposes to Graves disease (GD), with a reportedly indolent course. OBJECTIVE: To determine the type, frequency, and course of thyroid dysfunction (TD) in a cohort of alemtuzumab …
CONTEXT: Alemtuzumab, a highly effective treatment for multiple sclerosis (MS), predisposes to Graves disease (GD), with a reportedly …
Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management.
Mahzari M, Arnaout A, Freedman MS. Mahzari M, et al. Can J Neurol Sci. 2015 Sep;42(5):284-91. doi: 10.1017/cjn.2015.48. Epub 2015 May 20. Can J Neurol Sci. 2015. PMID: 25990097 Review.
Alemtuzumab, an anti-CD52 monoclonal antibody, was recently approved for treatment of MS in Canada, having shown to significantly reduce relapses and disability in patients, particularly those who relapsed despite first line treatment. Offsetting its benefit however, is th …
Alemtuzumab, an anti-CD52 monoclonal antibody, was recently approved for treatment of MS in Canada, having shown to significantly red …
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.
Dayan CM, Lecumberri B, Muller I, Ganesananthan S, Hunter SF, Selmaj KW, Hartung HP, Havrdova EK, LaGanke CC, Ziemssen T, Van Wijmeersch B, Meuth SG, Margolin DH, Poole EM, Baker DP, Senior PA. Dayan CM, et al. Mult Scler J Exp Transl Clin. 2023 Jan 3;9(1):20552173221142741. doi: 10.1177/20552173221142741. eCollection 2023 Jan-Mar. Mult Scler J Exp Transl Clin. 2023. PMID: 36619856 Free PMC article.
RESULTS: Thyroid events were reported for 378/811 (46.6%) alemtuzumab-treated patients. ...Multiple sclerosis outcomes of those with and without thyroid events were similar. CONCLUSION: Adjudicated thyroid events occurring over 6 years for alemtuzum …
RESULTS: Thyroid events were reported for 378/811 (46.6%) alemtuzumab-treated patients. ...Multiple sclerosis outcomes of thos …
Alemtuzumab-related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onset.
Yap SM, Dillon M, Crowley RK, McGuigan C. Yap SM, et al. Mult Scler J Exp Transl Clin. 2020 Jun 18;6(2):2055217320933928. doi: 10.1177/2055217320933928. eCollection 2020 Apr-Jun. Mult Scler J Exp Transl Clin. 2020. PMID: 32612846 Free PMC article.
BACKGROUND: Autoimmune thyroid disease (AITD) occurs in 40%-50% of alemtuzumab-treated persons with multiple sclerosis (pwMS), most of whom will develop Graves' Disease (GD). ...All symptomatic GD cases were age 32 years when starting alemtuzumab ( = 0.60, p …
BACKGROUND: Autoimmune thyroid disease (AITD) occurs in 40%-50% of alemtuzumab-treated persons with multiple sclerosis (pwMS), …
Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
Decallonne B, Bartholomé E, Delvaux V, D'haeseleer M, El Sankari S, Seeldrayers P, Van Wijmeersch B, Daumerie C. Decallonne B, et al. Acta Neurol Belg. 2018 Jun;118(2):153-159. doi: 10.1007/s13760-018-0883-2. Epub 2018 Jan 25. Acta Neurol Belg. 2018. PMID: 29372482 Free PMC article.
However, practical clinical guidance in case of abnormal thyroid-related findings prior to or after alemtuzumab treatment is currently lacking. Therefore, a Belgian taskforce consisting of MS and thyroid experts was created in 2016, with the objective of issu …
However, practical clinical guidance in case of abnormal thyroid-related findings prior to or after alemtuzumab treatment is c …
Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: A real-life and monocentric experience at a tertiary-level centre.
Manso J, Zhu YH, Margoni M, Rinaldi F, Censi S, Carducci S, Cosma C, Plebani M, Gallo P, Mian C. Manso J, et al. Clin Endocrinol (Oxf). 2022 Sep;97(3):331-338. doi: 10.1111/cen.14616. Epub 2021 Nov 1. Clin Endocrinol (Oxf). 2022. PMID: 34724236
OBJECTIVE: Alemtuzumab-induced autoimmune thyroid events (AIATEs) are the most common adverse effects observed in relapsing-remitting multiple sclerosis (RRMS) patients. ...RESULTS: AIATEs developed in 39% of patients a mean 17 months 11 after the first cycle of …
OBJECTIVE: Alemtuzumab-induced autoimmune thyroid events (AIATEs) are the most common adverse effects observed in relapsing-re …
Alemtuzumab-Induced Autoimmune Thyroid Dysfunction.
Ragavan S, Elhelw O, Majeed W, Kyriacou A, Syed A. Ragavan S, et al. Cureus. 2022 Mar 1;14(3):e22751. doi: 10.7759/cureus.22751. eCollection 2022 Mar. Cureus. 2022. PMID: 35371892 Free PMC article.
We discuss the pathophysiological role of stimulating and blocking thyrotropin receptor antibodies in the development of alemtuzumab-induced autoimmune thyroid dysfunction and clinical challenges posed by spontaneous, bidirectional switching between hyperthyroidism …
We discuss the pathophysiological role of stimulating and blocking thyrotropin receptor antibodies in the development of alemtuzumab- …
Thyroid and Adrenal Dysfunction in Hemoglobinopathies Before and After Allogeneic Hematopoietic Cell Transplant.
Mandava M, Lew J, Tisdale JF, Limerick E, Fitzhugh CD, Hsieh MM. Mandava M, et al. J Endocr Soc. 2023 Oct 31;7(12):bvad134. doi: 10.1210/jendso/bvad134. eCollection 2023 Nov 2. J Endocr Soc. 2023. PMID: 37953902 Free PMC article.
METHODS: We retrospectively reviewed patients who enrolled in 4 nonmyeloablative HCT regimens with alemtuzumab and total body irradiation (TBI). Baseline and annual post-HCT data were compared, which included age, sex, sickle phenotype, thyroid panel (total T3, free …
METHODS: We retrospectively reviewed patients who enrolled in 4 nonmyeloablative HCT regimens with alemtuzumab and total body irradia …
135 results